Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Leukemia, Myeloid, Chronic-Phase 32Leukemia 28Leukemia, Myeloid, Acute 18Breast Neoplasms 18Recurrence 15Prostatic Neoplasms 14Leukemia, Lymphocytic, Chronic, B-Cell 13Neoplasm Metastasis 12Blast Crisis 12Multiple Myeloma 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 11Pancreatic Neoplasms 10Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Lung Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 7Glioblastoma 7Melanoma 6Lymphoma 6Glioma 6Rectal Neoplasms 5Philadelphia Chromosome 5Ovarian Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Hematologic Neoplasms 5

Interventions

Imatinib Mesylate 5venetoclax 1ruxolitinib 1pevonedistat 1nilotinib 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypereosinophilic Syndrome × Dasatinib × Clear all
NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡